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Abstract 1	
Context: Controversy exists as to the optimal salvage modality in radio-recurrent 2	
prostate cancer. There is currently an absence of randomised-controlled trials 3	
comparing the oncological, toxicity and functional outcomes of salvage radical 4	
prostatectomy (SRP), salvage high-intensity focused ultrasound (SHIFU), salvage 5	
brachytherapy (SBT) and salvage cryotherapy (SCT). 6	
 7	
Objective: To carry out a meta-regression analysis to determine if there is a 8	
difference in oncological, toxicity and functional outcomes using data from original 9	
publications of salvage modalities in the post-radiation setting. 10	
Evidence acquisition: We performed a critical review of PubMed/Medline citations 11	
according to the Preferred Reporting Items for Systematic Review and Meta-analysis 12	
(PRISMA) statement. We included 63 articles in the analysis; 25 SRP, 8 SHIFU, 16 13	
SCT and 14 SBT. 14	
Evidence synthesis: Median values of the following variables were extracted from 15	
each study; patient age, length of follow-up, prostate specific antigen (PSA) before 16	
salvage therapy, PSA before radiotherapy, Gleason score before radiotherapy and 17	
time interval between radiotherapy and salvage therapy. Functional, toxicity and 18	
oncological outcomes were measured according to the rate of impotence, 19	
incontinence, fistula formation, urethral strictures and biochemical recurrence. Meta-20	
regression adjusting for confounders found no significant difference in oncological 21	
outcomes between SRP and non-surgical salvage modalities. SBT, SCT and SHIFU 22	
appear to have better incontinence outcomes compared to SRP. No significant 23	
difference in toxicity outcomes between modalities was found.  24	
	 3	
Conclusions: Oncological outcomes are comparable between SRP and all three non-25	
surgical salvage modalities. We found no significant differences in toxicity outcomes 26	
between modalities. SRP however appears to be associated with worse rates of 27	
urinary incontinence compared to SBT, SCT and SHIFU. 28	
 29	
Patient Summary: We performed a meta-regression analysis to compare oncological, 30	
functional and toxicity outcomes between SRP and non-surgical salvage modalities. 31	
We conclude that oncological and toxicity outcomes appear to be similar however 32	
SBT, SCT and SHIFU are associated with better continence outcomes. 33	
 34	
1. Introduction 35	
For more than two decades external-beam radiation therapy (ERBT) and low-dose 36	
rate brachytherapy (LDR-BT) have been considered standard practice for the 37	
treatment of patients with clinically localised low-risk prostate cancer. Over the years 38	
technological advances in this field have seen changes in the delivery of radiotherapy. 39	
The integration of various forms of image-guided radiotherapy (IGRT) for ERBT and 40	
brachytherapy and delivery with intensity-modulated radiotherapy (IMRT) have 41	
enabled accurate dose escalation to improve outcomes and reduce toxicity [1]. 42	
Radiobiological models have also indicated that prostate cancer cells are more 43	
sensitive to doses delivered in larger fraction sizes than in smaller frequent doses [2]. 44	
Our understanding of this has been critical in the introduction and evolution of high-45	
dose-rate brachytherapy (HDR-BT), stereotactic body radiotherapy and proton beam 46	
therapy. The introduction of higher radiation doses in addition to the use of adjuvant 47	
or neo-adjuvant androgen deprivation therapy (ADT) have both led to improved 48	
outcomes leading to the hypothesis that this combination would likely produce 49	
	 4	
additive improvements [3]. Even in the current era of dose-escalated radiotherapy for 50	
prostate cancer and its combination with ADT, biochemical recurrence is not 51	
uncommon occurring in approximately 20 to 30% of patients. In a study by Zelefsky 52	
et al post-treatment biopsies showed that 15 to 20% of patients treated with dose-53	
escalated radiotherapy have residual disease, suggesting at least a high incidence of 54	
local failure [4]. 55	
 56	
According to European and British urological guidelines, therapeutic options in 57	
patients with biochemical recurrence after primary radiation therapy can include  58	
salvage radical prostatectomy (SRP), salvage High-Intensity Focused Ultrasound 59	
(SHIFU), salvage cryotherapy (SCT) and salvage brachytherapy (SBT). However 60	
these guidelines advise that strong recommendations regarding the choice of any of 61	
these techniques cannot be made as the available evidence for these treatment options 62	
is of very low quality. This is because there are currently no randomised trials to 63	
compare the different modalities of salvage treatment in terms of oncological, 64	
functional and toxicity outcomes. The majority of available data comes from single- 65	
or multi-institutional retrospective or prospective studies with short to intermediate 66	
follow-up. SRP appears to be the most popular salvage modality in the post radiation 67	
setting based on the number of studies published in the literature. However the 68	
decision as to which modality to use is largely based on institutional practice and the 69	
availability of a particular technology rather than high quality evidence. Evaluating 70	
the relative effectiveness of various salvage treatments in terms of relative cancer 71	
control and treatment-related morbidity has proved challenging. This is because of 72	
differing treatment-specific definitions of biochemical recurrence, a lack of 73	
standardised reporting system of toxicity outcomes and the large heterogeneity 74	
	 5	
between studies in duration of follow-up, patient demographics, tumour risk profiles 75	
in terms of prostate specific antigen (PSA) value and Gleason score as well as the 76	
interval between radiotherapy and salvage therapy.  To date the only studies 77	
attempting to compare these modalities have been systematic reviews [5-7]. 78	
 79	
To help inform further discussion on this topic we carried out a meta-regression 80	
analysis to compare treatment failure rates, functional outcomes and toxicity between 81	
the different available salvage options for radio-recurrent disease. Our primary 82	
interest was to compare reported outcomes between the most commonly reported 83	
salvage modality, SRP and non-surgical modalities. 84	
 85	
2. Evidence acquisition 86	
 87	
2.1 Search strategy 88	
A systematic review of the literature was conducted using PubMed/Medline electronic 89	
databases. The search was restricted to English-Language articles from January 1, 90	
1994 and December 31, 2014. Search terms included ‘prostate cancer recurrence’, 91	
‘prostate salvage therapy’, ‘radio-recurrent prostate cancer’, ‘local salvage treatment’, 92	
‘SRP’, ‘SCT’, ‘SBT’ and ‘SHIFU’. We combined the search terms ‘prostate cancer 93	
recurrence’ with ‘SHIFU’ OR ‘SRP’ OR ‘SCT’ OR ‘SBT’ for four separate searches. 94	
 95	
2.2 Inclusion criteria 96	
All authors participated in the design of the search strategy and inclusion criteria. Our 97	
procedure for evaluating records identified during the literature search followed the 98	
Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) 99	
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criteria. We included only original articles involving salvage therapy in the post 100	
radiation setting. Eligibility criteria for selecting studies included (1) a diagnosis of 101	
recurrent prostate cancer after primary radiotherapy (2) studies reporting oncological 102	
outcomes in terms of biochemical recurrence rates (3) studies reporting 103	
comprehensively on functional and toxicity outcomes in terms of incontinence, 104	
impotence, fistula formation and urethral stricture. Any studies commenting on 105	
salvage treatments whereby the primary form of therapy was not radiotherapy were 106	
excluded from the analysis. The final list of included articles was selected with the 107	
consensus of all collaborating authors, verifying that they met the inclusion criteria. 108	
 109	
 110	
2.3 Data collated 111	
The following data were extracted from each study if available: first author; study 112	
size; median age; median follow-up duration; Gleason score prior to primary 113	
radiotherapy; median PSA prior to primary radiotherapy; median clinical stage prior 114	
to primary radiotherapy; median interval between primary radiotherapy and salvage 115	
therapy; administration of adjuvant ADT at the time of primary radiotherapy; median 116	
PSA prior to salvage therapy, Gleason score prior to salvage therapy; median clinical 117	
stage prior to salvage therapy. Functional outcomes were determined by measuring  118	
impotence and  incontinence rates and toxicity outcomes evaluated by measuring  119	
fistula and urethral stricture formation rates as reported by the individual studies. 120	
Oncological outcomes were determined according to biochemical recurrence rate as 121	
reported by the individual study. As a pragmatic approach we used each study’s 122	
predefined criteria for biochemical failure, continence and potency recognizing the 123	
lack of consistency of these definitions within and across treatment types.  124	
	 7	
2.4 Data Analysis 125	
The outcomes of biochemical recurrence, impotence, incontinence, fistula formation, 126	
and urethral strictures were individually compared between salvage therapies using 127	
meta-regression analysis with salvage modality included as a moderator. The meta-128	
regression analysis consisted of fitting a logistic mixed effects model to each of the 129	
outcome variables using the “rma.glmm” function within the “metafor” package [8] in 130	
R software [9] with an explanatory factor variable for salvage modality. For 131	
oncological outcome defined as biochemical relapse after salvage, the model adjusted 132	
for a further six moderators: age, length of follow-up, PSA before radiotherapy, PSA 133	
before salvage therapy, Gleason score before radiotherapy and time interval between 134	
radiotherapy and salvage therapy. For both toxicity outcomes and incontinence as a 135	
functional outcome the meta-regression model adjusted for age, length of follow-up, 136	
PSA before salvage therapy, and PSA before radiotherapy and Gleason score before 137	
radiotherapy. Unfortunately no covariate adjustment was possible for impotence. The 138	
reason behind this modeling strategy was that many studies had missing data on the 139	
moderators, which reduced the dataset available for analysis and hence caused 140	
problems with model fitting. We always aimed to include the maximum number of 141	
moderators possible in each analysis, and this meant that the analyses for some 142	
outcomes included more moderators than for others.  143	
 144	
The reported median was used to summarise the aforementioned moderators; except 145	
when missing, in which case the mean was used instead where available. A value of 146	
“0.5” was added to any zero frequencies prior to analysis. The amount of residual 147	
heterogeneity between studies was assessed by reporting the absolute value of 𝜏! 148	
(between-study variance) and the I²-statistic. Summary effect size differences in 149	
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outcomes between the different surgical modalities were expressed as odds ratios 150	
(OR) with 99% confidence intervals and p-values. Due to the high number of models 151	
and outcome variables considered in multiple testing, a 1% significance threshold was 152	
used to determine statistical significance. To investigate publication bias, funnel plots 153	
were constructed of sample size against model residuals calculated via linear meta-154	
regression models of logit-transformed proportions, with salvage therapy included as 155	
the only moderator.  156	
3. Evidence synthesis 157	
The literature search yielded 975 papers. These were then individually screened for 158	
their suitability for inclusion in this study. 912 articles were excluded from the study 159	
resulting in 63 articles [10-71] being finally included in the analysis (Figure 1). One 160	
of the SCT studies included 2 separate cohorts of patients who underwent SCT, the 161	
outcomes of which we considered separately [45] therefore a total of 64 studies were 162	
included in the analysis. 25 for SRP; eight SHIFU, 17 SCT and 14 SBT. Five of the 163	
studies provided no data on mean or median age, and three did not record the duration 164	
of follow-up. 30 studies had no data on PSA prior to primary radiotherapy and seven 165	
papers had no data on PSA prior to salvage therapy.  In addition, 33 of the studies did 166	
not mention the Gleason Score prior to initial radiotherapy and 22 studies provided no 167	
data on the interval between radiotherapy and salvage therapy. The total number of 168	
patients was 4564 with a median study size of 40 (range 4-404). Further base line 169	
characteristics of the original publications identified by the literature search are shown 170	
in table 1. A funnel plot of the model residuals against sample size showed no clear 171	
evidence of publication bias for biochemical recurrence as an outcome variable 172	
(Figure 2). However there were some limited indications of publication bias when 173	
considering toxicity and functional outcomes particularly that of incontinence. 174	
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The cohort size of each study and the overall percentage relapse rate at any time as 175	
well as toxicity and functional outcomes are represented as bubble plots (Figure 3). 176	
Overall SCT included the largest population sizes (110 subjects on average) while the 177	
SBT studies included the smallest number of patients (26 subjects on average). 178	
Weighted summary statistics for age, length of follow up, PSA before salvage 179	
therapy, PSA before radiotherapy Gleason score before radiotherapy, interval between 180	
radiotherapy and salvage therapy and oncological, toxicity and functional outcomes 181	
for each salvage modality is displayed in Table 2.  182	
 183	
3.1 Meta-regression analysis for biochemical relapse 184	
The bubble plot for biochemical recurrence showed no obvious visual difference 185	
between the salvage modalities (Figure 2) and this was confirmed in the meta-186	
regression analyses. Two analyses were done for biochemical recurrence. The first 187	
adjusted for no additional moderators (Model 1) and included 61 studies. This 188	
analysis showed no significant difference in biochemical relapse between SRP and the 189	
non-surgical salvage modalities (SBT relative to SRP OR 0.98 99%CI 0.493-1.95, 190	
p=0.939, SCT relative to SRP OR 1.49 99%CI 0.816-2.73, p=0.087, SHIFU relative 191	
to SRP OR 1.17 99% CI 0.537-2.56, p=0.60). A further analysis to compare the 192	
oncological outcomes between the non-surgical salvage modalities revealed no 193	
significant difference in biochemical recurrence either (SBT relative to SHIFU OR 194	
0.836 99%CI 0.355-1.97, p=0.590, SCT relative to SHIFU OR 1.27 99%CI 0.577-195	
2.81, p=0.430, and SBT relative to SCT OR 0.656 99%CI 0.326-1.32, p=0.121).     196	
The second analyses adjusted for the following variables: age, PSA before 197	
radiotherapy and salvage therapy, Gleason score before radiotherapy, follow-up 198	
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duration and interval between radiotherapy and salvage therapy (Model 3). After 199	
accounting for the above variables 18 studies were eligible for the second analysis. 200	
The residual heterogeneity between studies for this analysis was estimated to be zero. 201	
The meta-regression analysis following adjustment for these variables again showed 202	
no significant difference in biochemical recurrence rates between the SRP and the 203	
other non-surgical salvage modalities (SBT relative to SRP OR 0.623 99% CI 0.237-204	
1.64, p=0.207, SCT relative to SRP OR 0.98 99%CI 0.294-3.27, p=0.966, SHIFU 205	
relative to SRP OR 1.32 99% CI 0.419-4.16, p=0.533. Subsequent analysis of the 206	
non-surgical salvage modalities did not find one superior to the other in this respect 207	
either (Table 3). These results are consistent with systematic reviews on the topic 208	
where no difference in oncological outcomes between the different salvage modalities 209	
is demonstrated.   210	
 211	
3.2 Meta-regression analysis for toxicity outcomes 212	
The bubble plots for urethral stricture and fistula formation showed no visual 213	
difference between the four salvage modalities (Figure 2). For both urethral stricture 214	
and fistula formation two meta-regression analyses were done. The first adjusted for 215	
no additional moderators and included 37 and 30 studies for fistula and urethral 216	
stricture respectively. In this first analysis no significant difference was demonstrated 217	
between SRP and the non-surgical salvage modalities in the rate of fistula formation 218	
(Table 3). In addition the first meta-regression analysis demonstrated no significant 219	
difference in the rate of urethral stricture formation between SRP and the non-surgical 220	
salvage modalities (SBT relative to SRP OR 0.603 99%CI 0.128-2.85, p=0.402, 221	
SCT relative to SRP OR 0.219 99%CI 0.0309-1.56, p=0.046, SHIFU relative to 222	
	 11	
SRP OR 0.884 99% 0.293-2.67, p=0.775). The second meta-regression adjusted for 223	
age, length of follow-up, PSA before radiotherapy, PSA before salvage therapy and 224	
Gleason score before radiotherapy for both toxicity outcomes. A total of 18 studies 225	
and 14 studies were eligible for inclusion in the second analysis for fistula and 226	
urethral strictures respectively. The residual heterogeneity between studies for both 227	
analyses was estimated to be zero. Following adjustment for these variables the 228	
analysis again found no significant difference in the rates of urethral strictures and 229	
fistula between SRP and all the non-surgical salvage modalities across the meta-230	
regression analysis. A further analysis focusing only on comparing non-surgical 231	
modalities for both these outcomes similarly found no significant differences (Table 232	
3). These results suggest that none of the salvage options appear to have an advantage 233	
in the context of a reduced risk of complications. 234	
 235	
3.3 Meta-regression analyses for functional outcomes 236	
The bubble plot for incontinence demonstrated an apparent benefit of all three non-237	
surgical salvage modalities compared to SRP when considering the rate of 238	
incontinence. This was  particularly the case for SBT and SCT and less so for SHIFU.  239	
(Figure 2). 240	
For incontinence two meta-regression analyses were undertaken. The first adjusted for 241	
no additional moderators and included a total of 49 studies. In this analysis SBT and 242	
SCT had significantly better outcomes in terms of incontinence compared to SRP. 243	
However in this analysis SHIFU did not demonstrate significantly better incontinence 244	
outcomes compared to SRP at the p<0.01 level of significance (Table 3). A further 245	
analysis between the non-surgical salvage modalities found that SBT and SCT had 246	
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significantly better incontinence outcomes compared to SHIFU, however there was no 247	
significant difference when comparing SCT to SBT (SBT relative to SHIFU OR 248	
0.184 99%CI 0.0445-0.761, p=0.002, SCT relative to SHIFU OR 0.233 99%CI 249	
0.0727-0.749, p=0.001, SBT relative to SCT OR 0.789 99%CI 0.211-2.95, p=0.644) 250	
The second analysis adjusted for age, length of follow-up, PSA before radiotherapy, 251	
PSA before salvage therapy, and Gleason score before radiotherapy. A total of 18 252	
studies were eligible for inclusion in this analysis. The residual heterogeneity was 253	
calculated to be 65.67% implying that substantial between-chort differences remain 254	
even after taking into account surgical modality and other factors.. Following 255	
adjustment for these variables there was evidence that all three non-surgical salvage 256	
modalities were significantly superior to SRP in terms of incontinence outcomes 257	
(SBT relative to SRP OR 0.00595 99%CI 0.000245-0.144, p<0.001, SCT relative to 258	
SRP 0.0142 99%CI 0.00209-0.0965, p<0.001 SHIFU relative to SRP OR 0.0822 259	
99%CI 0.00868-0.778,p=0.004). When considering the non-surgical salvage 260	
modalities alone SCT was found to be superior to SHIFU. In contrast to the first 261	
analysis there was insufficient evidence that SBT has improved incontinence 262	
outcomes compared to SHIFU (table 3) These results suggest that of all modalities, 263	
SRP appears to have the highest risks of urinary incontinence. A caveat to this is the 264	
high residual heterogeneity in our analysis.  265	
Impotence outcomes were the poorest recorded parameter and are therefore the least 266	
reliable in our study. The bubble plots for impotence demonstrated an apparent 267	
benefit of SCT over SRP however due to the limited available data on impotence 268	
outcomes an adjusted meta-regression model was not possible. Furthermore SHIFU 269	
was not included in this analysis as only one of the included studies on SHIFU 270	
reported impotence outcomes; therefore only SRP, SCT and SBT were considered in 271	
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the statistical analysis. A total of 19 studies were included in the analysis. The 272	
residual heterogeneity was calculated to be 92.64%, which is very high and suggests 273	
that substantial between-study differences in reported impotence rates remain even 274	
after taking into account surgical modality. The only finding was that SCT might have 275	
superior outcomes in terms of impotence compared to SRP. There was no other 276	
significant difference found between modalities; although as stated above, we were 277	
unable to compare SHIFU with the other modalities (SBT relative to SRP OR 0.581 278	
99%CI 0.0162-20.9, p=0.664, SCT relative to SRP OR 0.0567 99%CI 0.00428-279	
0.751, p=0.005, SBT relative to SCT OR 10.3 99%CI 0.217-484, p=0.097). 280	
 281	
3.4 Discussion 282	
SRP is currently the most widely reported salvage modality in the literature and there 283	
has been a resurgence in its popularity with the introduction of robotic assisted 284	
prostatectomy [72]. More recently the advent of new minimally invasive modalities 285	
and the concept of focal therapy has also been increasingly applied in the salvage 286	
therapy context [73,74]. There is however currently no consensus as to which salvage 287	
modality should be used or is optimal for radio-recurrent disease. Our meta-regression 288	
analysis of the current available literature showed no significant difference in 289	
oncological outcomes between SRP and the other three non-surgical salvage 290	
modalities. Also further analyses between the non-surgical salvage modalities did not 291	
find one more superior to the other in this respect. With regard to toxicity outcomes 292	
our results suggest that there is again no significant difference in the rate of fistula and 293	
urethral stricture formation between SRP and the other non-surgical salvage 294	
modalities.  SRP however was associated with a greater rate of incontinence in 295	
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comparison to all three non-surgical salvage modalities. Of note, despite correction 296	
for variables potentially associated with incontinence outcomes we still identified a 297	
degree of residual heterogeneity in the results. This coupled with the possibility of 298	
publication bias as demonstrated by the funnel plots urges us to interpret our results 299	
with some caution. Nevertheless, our analysis of incontinence outcomes agree with a 300	
systematic review by Parekh et al who noted that incontinence rates were highest 301	
among SRP patients with a rate of 49.7% across series [6]. Publication bias and 302	
heterogeneity was also identified in our analysis of potency outcomes primarily due to 303	
the limited data reporting. As a result we are unable to draw any robust conclusions as 304	
of a superior modality with regards this outcome.. 305	
This study has a number of inherent limitations. Data was extracted from published 306	
manuscripts, rather than from original patient data, so a degree of reporting bias is 307	
inevitable. Not all studies reported patient age, length of follow-up, PSA before 308	
salvage therapy, PSA before radiotherapy, and Gleason score before radiotherapy, and 309	
time between radiotherapy and salvage therapy, which meant that missing data was 310	
extensive and the data available for analysis was often limited. For every outcome we 311	
therefore attempted to adjust for as many confounders possible in the final meta-312	
regression model. As mentioned, our assessment of residual heterogeneity indicates 313	
that for incontinence and impotence outcomes there remains a significant amount of 314	
unexplained variability in the data that we have not been able to account for. We also 315	
note the relative short follow-up duration of studies reporting outcomes for SCT, SBT 316	
and SHIFU compared to SRP. Studies with longer follow-up duration will be 317	
necessary to accurately compare SRP with the non-surgical salvage modalities. 318	
Finally the interpretation of biochemical failure in our study depended on the 319	
definition used by individual published series and was based on a pragmatic approach 320	
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due to the diverse interpretation of relapse between the salvage modalities. 321	
Nevertheless despite these limitations our conclusions are in strong agreement with 322	
the findings of recently published systematic reviews, which have found no 323	
significant differences in oncological outcomes between the salvage modalities but 324	
suggest that SRP may have worse functional outcomes particularly in the rates of 325	
incontinence.  326	
 327	
4. Conclusion 328	
This study is unique in that it endeavoured to adjust for heterogeneity prior to 329	
statistical analysis and is the first to use a meta-regression model to compare salvage 330	
modalities. Our findings in this study reinforce conclusions from systematic reviews 331	
suggesting that current salvage modalities appear to have similar oncological and 332	
toxicity outcomes. In particular, SRP does not appear to confer any added benefit in 333	
terms of disease control compared to more minimally invasive approaches but instead 334	
may potentially increase functional debility. The wide variation in study parameters, 335	
outcome measures and endpoints reinforce the urgent need for prospective 336	
randomised controlled studies directly comparing between modalities as well as 337	
standardised definitions of outcomes and longer follow-up times. Until then we hope 338	
our data and findings will help inform clinicians and patients when deciding between 339	
different salvage therapy options. 340	
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Radiotherapy, IMRT; Intensity-Modulated Radiotherapy, HDR-BT; High-Dose-Rate 
Brachytherapy, ADT; Androgen Deprivation Therapy, PSA; prostate specific antigen, 
PRISMA; Preferred Reporting Items for Systematic Reviews and Meta-analyses criteria. 
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